Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
Department of Nephrology, The First Medical Center, Chinese PLA General Hospital, Medical School of Chinese PLA, Chinese PLA Institute of Nephrology, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China.
J Med Virol. 2023 Aug;95(8):e29007. doi: 10.1002/jmv.29007.
There is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID-19), especially on the application of 2'-deoxy-2'-β -fluoro-4'-azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients. After matching for age, sex, and other factors, 182 patients in the basic treatment group and 182 in the FNC group were included. The negative nucleic acid conversion rate of the FNC group was significantly higher than that of the basic treatment group, and viral loads, interleukin-6, and C-reactive protein were significantly lower than those of the basic treatment group (p < 0.05). There were no significant differences in liver function, renal function, or the number of adverse events between the two groups (p > 0.05). In conclusion, our study has provided novel evidence suggesting that the FNC scheme may be safe and effective compared to the basic treatment of hemodialysis patients with common COVID-19.
目前尚无关于接受血液透析治疗的 2019 冠状病毒病（COVID-19）患者的抗病毒研究，特别是关于 2'-脱氧-2'-β-氟-4'-叠氮胞苷（阿兹夫定，FNC）抗病毒治疗的应用。我们进行了一项多中心观察性研究，纳入了 1008 名血液透析患者。经过年龄、性别等因素的匹配，基础治疗组纳入 182 例患者，FNC 组纳入 182 例患者。FNC 组的核酸转阴率明显高于基础治疗组，病毒载量、白细胞介素-6 和 C 反应蛋白明显低于基础治疗组（p<0.05）。两组的肝功能、肾功能或不良事件的数量无显著差异（p>0.05）。总之，我们的研究提供了新的证据，表明与 COVID-19 普通血液透析患者的基础治疗相比，FNC 方案可能更安全、更有效。
